Research & Clinical Trials
|
Since the Division's inception in the early 1970s, it has been one of the premier research-oriented allergy centers in the nation. It has contributed many novel concepts in allergy and immunology and consistently published high-impact research articles in superior journals such as:
 Every year since its inception, members of the Allergy Division have had funding from NIH for research conducted in the division. In addition, many members have served in prestigious NIH study sections to evaluate research and education in the field of allergy and immunology. Some of the pioneering concepts and research activities are:
|
Available Resources
UTMB Health is home to several unique facilities and programs that support clinical research and provide world class clinical and research opportunities.
NIH NHLBI Proteomics Center
UTMB is one of seven institutions which are part of a new proteomics program launched by the NHLBI on August 15, 2010. Collectively, the participating centers were awarded $83.5 million. UTMB has been a part of the NHLBI Proteomics Initiative since 2002. The new network consists of Boston University, Johns Hopkins University, Massachusetts General Hospital, Stanford University, the University of California-Los Angeles, the University of Texas Health Sciences Center at San Antonio, and UTMB Health.
Institute for Translational Sciences
The ITS is the academic home of a five-year, $21.5 million Clinical Translational Sciences Award (CTSA) by the National Institutes of Health– National Center for Research Resources. The National CTSA Consortium, which currently includes 46 institutions, is working to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research.
Clinical Research Center
Child Health Research Center
Research Pharmacy
Aerospace Medicine Program
Affiliation with Shriners Burns Hospital
WHO Collaborating Center for Tropical Diseases
Research & Clinical Trials
Research is a central focus of UTMB's Division of Allergy and Immunology. Since the creation of the division in the early 1970s, it has been one of the region's premier research-oriented allergy centers. Our research focuses on advancing the understanding of allergic and immunologic disorders, as well as improving measures for diagnosis and treatment. Clinical trials are carried out under strict guidelines with great attention to participant safety.
Individuals choose to participate in clinical research for many reasons. Some like the idea of being able to receive treatment with promising therapies before they are approved by the Food and Drug Administration for widespread commercial use. Others have tried conventional treatments and are in search of a new option. Still others may participate in clinical research in efforts to advance science and medicine.
We currently are conducting studies on hereditary angioedema, asthma, and immunodeficiencies. New studies are added frequently; call to check with us about our latest research and trials.
For more information about research studies and clinical trials, please contact Dr. Rana Bonds or Dr. Andrew Grant at 409.772.2436.
|
The Division of Allergy & Immunology at UTMB provides state-of-the-art care for over 2,300 patients with various allergic and immunologic disorders per year. A major factor in the division's ability to provide the latest treatments is their participation in clinical trials of both therapeutics and diagnostics. These include:
 Placing a study at UTMB is a simple phone call or email away. By contacting the Division, an investigator can be identified and copies of CVs and licenses obtained.
For more information contact: |
The UTMB Center for Global Health Education (CGHE) is dedicated to the training of tomorrow's global health work force to improve health for the people of Texas and around the world. Check out their website for more information on the global health programs and education going on in our department.
Featured Videos
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.
Currently available protocols are:- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.